Sutro Biopharma, Inc., A Clinical-Stage Oncology Company Pioneering Site-Specific And Novel-Format Antibody Drug Conjugates (Adcs), Today Announced That The First Patient Has Been Dosed In A Phase 1 Study Of An Investigational Candidate Resulting From The Collaboration Between Sutro And Merck, Known As Msd Outside The United States And Canada, For The Development Of A Novel Cytokine Derivative Therapeutic For The Treatment Of Cancer. As A Result Of This Milestone, Sutro Will Receive A $10 Million Payment From Merck.
